International Institute of Anticancer Research

Call for papers

Special Issue of Anticancer Research on NEW ANTICANCER AGENTS 2024

TOPICS:    A. Experimental studies on “New Anticancer Agents”

1. 1. Synthesis and evaluation in vitro and in vivo
   2. Mechanism of action
   3. Reversal of resistance to anticancer agents
   4. Oncolytic viruses

       B. Clinical studies on “New Anticancer Agents”

1. 1. Pharmacology
   2. Clinical trials
   3. Combination chemotherapy
   4. Immunotherapeutic agents
   5. New methodologies in drug delivery
   6. Vaccines

Publication date: March 1, 2024
Submission deadline: December 31, 2023
Instructions for the preparation and submission of reviews and original articles: www.iiar-anticancer.org

Special Issue on Emerging Technologies in Cancer Research

High-throughput genomic technologies continuously advance and offer new opportunities to better understand and treat cancer. The past decade has seen a plethora of next-generation sequencing and data analysis studies, allowing us to map the genomic landscapes of various cancer types, while single cell analyses are shedding light on tumor heterogeneity. Groundbreaking new technologies, such as spatial omics, can give us unprecedented insight into the spatiotemporal tumor architecture and micro-environment. In this regard, this special issue aims to bring together review articles, experimental and clinical studies on the following topics:

– Whole-genome sequencing
– Single-cell genomics
– Mutational signatures
– Spatial transcriptomics
– Epigenomics
– Multi-omics
– Tumor architecture
– Tumor progression
– Data analysis methods / bioinformatics /machine learning
– Tumor heterogeneity
– Circulating tumor cells
– Precision medicine
– Tumor microenvironment interactions
– Computational immunology
– New therapeutic targets

Publication date: December 1, 2023; Submission deadline: November 3, 2023.
Instructions for the preparation and submission of reviews and original articles.

Anticancer Research, In Vivo, Cancer Genomics & Proteomics, and Cancer Diagnosis & Prognosis are independent international journals, published by the International Institute of Anticancer Research (IIAR), and have had no relation or association with other publishers since their establishment.

At the IIAR, we are committed to maintaining the highest content quality and the most rapid processing of submitted articles to our four journals.

All submitted articles are peer-reviewed to secure a valid assessment. Our preliminary review includes a detailed assessment of the suitability and validity of the conclusions of all cited references.

We value the support of our policy by our Authors and Readers and we look forward to receiving comments and suggestions for the
continuous improvement of our services.

Articles in ANTICANCER RESEARCH are fully available to everyone as open access 2 years after publication.
IN VIVO (from January 2017) and CANCER GENOMICS & PROTEOMICS (from January 2013) are published online-only with open access.
CANCER DIAGNOSIS & PROGNOSIS (from March 2021) is published online-only with open access.